Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Emmanuel Mitry

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5474-9146; OpenAlex author ID A5001546426. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
81
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 16

  1. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  2. Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/op-25-00358↗
  3. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  4. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  5. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  6. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  7. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  8. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.11.035↗
  9. Management and outcomes of brain metastases from pancreatic adenocarcinoma: a pooled analysis and literature review. Co-author DOI 10.3389/fonc.2023.1326676↗
  10. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  11. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  12. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  13. Unbalance between plasma levels of Protein Z and protein Z-dependent inhibitor in patients with colorectal and pancreatic cancer: a pilot study. Co-author DOI 10.1016/j.thromres.2013.11.015↗
  14. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  15. Effectiveness of combined endoscopic ultrasound-guided fine-needle aspiration biopsy and stenting in patients with suspected pancreatic cancer. Co-author DOI 10.1097/meg.0b013e328357cdfd↗
  16. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results]. First author DOI 10.1684/bdc.2011.1494↗

Closest collaborators

The 25 strongest of 81 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aurélien Lambert · 5 shared papers, 2024–2026 · strength 0.87
  2. Brice Chanez · 5 shared papers, 2022–2026 · strength 0.85
  3. Rémy Nicolle · 5 shared papers, 2022–2026 · strength 0.77
  4. Nelson Dusetti · 5 shared papers, 2022–2026 · strength 0.77
  5. Pascal R. Hammel · 6 shared papers, 2012–2026 · strength 0.68
  6. Jean‐Baptiste Bachet · 5 shared papers, 2012–2026 · strength 0.65
  7. Vinciane Rebours · 4 shared papers, 2022–2026 · strength 0.63
  8. Jerome F. Cros · 4 shared papers, 2022–2026 · strength 0.63
  9. Thierry Conroy · 6 shared papers, 2011–2026 · strength 0.62
  10. Juan Iovanna · 5 shared papers, 2012–2024 · strength 0.60
  11. James Biagi · 3 shared papers, 2024–2026 · strength 0.51
  12. Anthony Turpin · 3 shared papers, 2024–2026 · strength 0.51
  13. Daniel John Renouf · 3 shared papers, 2024–2026 · strength 0.51
  14. Jean‐Luc Van Laethem · 4 shared papers, 2012–2025 · strength 0.50
  15. Nicolas Alejandro Fraunhoffer · 3 shared papers, 2023–2026 · strength 0.49
  16. Teresa Mercade Macarulla · 3 shared papers, 2014–2025 · strength 0.38
  17. Alice Chia-Chi Wei · 2 shared papers, 2024–2026 · strength 0.36
  18. Jean‐Frédéric Blanc · 2 shared papers, 2024–2025 · strength 0.36
  19. Hans Prenen · 2 shared papers, 2024–2025 · strength 0.36
  20. Karen Paula Geboes · 2 shared papers, 2024–2025 · strength 0.36
  21. Lorenzo Pilla · 2 shared papers, 2024–2025 · strength 0.36
  22. Roberto Pazo-Cid · 2 shared papers, 2024–2025 · strength 0.36
  23. Jaime Feliú · 2 shared papers, 2024–2025 · strength 0.36
  24. Philippe Alexandre Cassier · 2 shared papers, 2024–2025 · strength 0.36
  25. Alexandre Harlé · 2 shared papers, 2024 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.